Session # n/a

Common Attributes in Mutation Carriers Identified in a 32-Gene Hereditary Cancer Panel.

The use of multi-gene panel testing (MGPT) with next generation sequencing (NGS) to detect hereditary cancer syndromes has become increasingly common. MGPT has identified more individuals with increased cancer risk than traditional methods, including mutations in genes that were not suspected. Which patients should have MGPT and what results may be found are common questions among clinicians, and the likelihood of finding a mutation is heavily considered in determining who should have testing. Our study aims to assess and compare the mutation frequencies among patients on CancerNextTM, an NGS panel of 22-32 genes during the time studied

• Authors: Laura Panos Smith; Carin Espenschied; Amal Yussuf; Yuan Tian; Dajun Qian; Tripti Paudyal
• Conference: European Cancer Congress (ECCO)
• Date: Sunday, Jan 29, 2017 9:00am - 6:00pm